银屑病患者接受生物制剂治疗的癌症风险:一项系统综述
该系统综述检索了截至2016年8月的随机对照试验、前瞻性队列研究和系统综述,评估银屑病患者接受生物制剂治疗的癌症风险。共纳入8项前瞻性队列研究,证据主要涉及TNF抑制剂(TNFi),仅一项研究涉及乌司奴单抗。结果显示TNFi治疗与非黑色素瘤皮肤癌(NMSC),尤其是鳞状细胞癌风险增加相关,但未发现其他癌症风险增加的证据。
要点
- TNFi治疗银屑病与非黑色素瘤皮肤癌风险增加相关
- 尤其鳞状细胞癌风险增加,需关注
- 未发现淋巴瘤、黑色素瘤等其他癌症风险增加
核心结论
- TNFi治疗银屑病患者与非黑色素瘤皮肤癌风险增加相关,尤其是鳞状细胞癌。
- 除NMSC外,未发现其他癌症(包括所有癌症、淋巴瘤、黑色素瘤、前列腺癌、结直肠癌和乳腺癌)风险增加的证据。
研究设计与样本
- 系统综述,检索MEDLINE、Embase和Cochrane Library(截至2016年8月)。
- 纳入报告银屑病患者暴露于生物治疗与对照人群癌症发病率的随机对照试验、前瞻性队列研究和系统综述。
- 共纳入8项前瞻性队列研究,证据主要涉及TNFi,仅一项研究涉及乌司奴单抗。
主要发现
- 与一般美国人群相比,TNFi治疗银屑病患者非黑色素瘤皮肤癌风险增加。
- 与接受TNFi治疗的类风湿关节炎人群相比,TNFi治疗银屑病患者非黑色素瘤皮肤癌风险增加。
- 鳞状细胞癌风险增加被特别报告。
- 未发现其他癌症(所有癌症、淋巴瘤、黑色素瘤、前列腺癌、结直肠癌和乳腺癌)风险增加的证据。
临床怎么用
- 银屑病患者使用TNFi治疗时应关注非黑色素瘤皮肤癌风险,尤其是鳞状细胞癌。
- 需持续进行癌症风险相关的药物警戒。
- NMSC信号需进一步研究,利用前瞻性收集数据并调整已知NMSC风险因素以确定生物治疗特异性风险。
局限性
- 研究存在重要局限性,包括对照臂选择问题。
- 对混杂因素调整不充分。
- 未考虑癌症潜伏期。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Biological therapies are highly effective in psoriasis, but have profound effects on innate and adaptive immune pathways that may negatively impact on cancer immunosurveillance mechanisms. OBJECTIVES: To investigate the risk of cancer in patients with psoriasis treated with biological therapy. METHODS: We searched MEDLINE, Embase, and the Cochrane Library (up to August 2016) for randomized controlled trials, prospective cohort studies and systematic reviews that reported cancer incidence in people exposed to biological therapy for psoriasis compared with a control population. RESULTS: Eight prospective cohort studies met our inclusion criteria. All the evidence reviewed related to tumour necrosis factor inhibitors (TNFi) with the exception of one study on ustekinumab. An increased risk of nonmelanoma skin cancer (NMSC), particularly squamous cell carcinoma, was reported with TNFi compared with both a general United States population and a rheumatoid arthritis population treated with TNFi. No evidence for increased risk of cancers (reported as all cancers, lymphoma, melanoma, prostate, colorectal and breast cancer) other than NMSC was identified. CONCLUSIONS: There were important limitations to the studies identified including choice of comparator arms, inadequate adjustment for confounding factors and failure to account for latency periods of cancer. There remains a need for ongoing pharmacovigilance in relation to cancer risk and biological therapy; the NMSC signal requires further investigation to determine the risk specifically attributable to biological therapy using prospectively collected data with adjustment for known NMSC risk factors.
引用
- Peleva E, Exton LS, Kelley K, et al. Risk of cancer in patients with psoriasis on biological therapies: a systematic review. Br J Dermatol. 2017. PMID: 28722163. doi:10.1111/bjd.15830
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。